Ehrlich Financial Group Takes Position in Glaukos Corporation $GKOS

Key Points

• Ehrlich Financial Group acquired a new position in Glaukos Corporation by purchasing 10,014 shares valued at approximately $1,034,000 during the second quarter of 2024.
• Glaukos has seen a number of institutional investors modify their holdings, with 99.04% of the stock currently owned by institutional investors.
• Analysts have set a consensus target price of $124.83 for Glaukos, with various ratings including one "Strong Buy" and ten "Buy" ratings.

Ehrlich Financial Group bought a new position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,014 shares of the medical instruments supplier's stock, valued at approximately $1,034,000.

A number of other large investors also recently modified their holdings of the company. Focus Partners Wealth bought a new stake in Glaukos during the 4th quarter valued at $379,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Glaukos by 3.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,349 shares of the medical instruments supplier's stock valued at $4,551,000 after buying an additional 984 shares during the last quarter. Nuveen Asset Management LLC increased its position in shares of Glaukos by 0.9% during the fourth quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock worth $47,226,000 after acquiring an additional 2,665 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Glaukos by 44.0% in the 4th quarter. ProShare Advisors LLC now owns 14,869 shares of the medical instruments supplier's stock worth $2,229,000 after acquiring an additional 4,542 shares during the last quarter. Finally, State of Wyoming raised its holdings in shares of Glaukos by 2.3% in the 4th quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock worth $487,000 after acquiring an additional 72 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Mizuho set a $130.00 price target on Glaukos in a research note on Thursday, July 31st. Wells Fargo & Company lifted their target price on Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. UBS Group increased their price target on Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Zacks Research downgraded shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Finally, William Blair upgraded shares of Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Glaukos presently has a consensus rating of "Moderate Buy" and an average target price of $124.83.

Glaukos Stock Performance

NYSE GKOS opened at $80.72 on Tuesday. The company has a market capitalization of $4.63 billion, a PE ratio of -48.92 and a beta of 0.77. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71. The company has a 50-day simple moving average of $93.06 and a 200 day simple moving average of $95.22.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same period in the prior year, the firm earned ($0.52) EPS. The company's revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. On average, research analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.